Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis - 20/04/21
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 9 |
| Iconografia | 7 |
| Video | 0 |
| Altro | 0 |
Highlights |
• | The recanalization rate of PVT was high in patients with anticoagulants treatment. |
• | The exacerbation risk of PVT was low in anticoagulants treatment group. |
• | The portal hypertension bleeding was low in PVT patients treated with anticoagulants. |
Summary |
Objective |
To investigate the efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis (PVT).
Methods |
PubMed, BioMed Central, Cochrane Library and Web of Science were retrieved to identify relevant literature. Forest plots were applied to display the results of the meta-analysis. The odds ratios (ORs) were used as the effect index for the enumeration data, and the effect size was expressed as 95% confidence intervals (CIs). Publication bias was evaluated by funnel plots and Egger's test.
Results |
Eight articles included 225 patients with liver cirrhosis and PVT receiving anticoagulants and 232 not receiving anticoagulants. The data demonstrated that the recanalization rate of PVT was significantly higher in patients with anticoagulant treatment than in patients without anticoagulant treatment (OR=5.60; 95% CI: 3.40–9.22; P<0.001). The exacerbation risk of PVT was significantly lower in patients with anticoagulant treatment than in patients without anticoagulant treatment (OR=0.15; 95% CI: 0.04–0.54; P<0.001). A significantly lower portal hypertension bleeding effect was observed in patients with anticoagulant treatment than in patients without anticoagulant treatment (OR=0.21; 95% CI: 0.10–0.45; P<0.001). Low molecular weight heparins (LMWH) were more effective in preventing the PVT exacerbation in liver cirrhosis patients with PVT than warfarin (OR=0.16; 95% CI: 0.08–0.35).
Conclusions |
Anticoagulants were effective and safe in treating patients with liver cirrhosis and PVT as they could increase the PVT recanalization rate and decrease the risks of PVT exacerbation and portal hypertension bleeding.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Anticoagulants, Liver cirrhosis, Portal hypertension bleeding, Warfarin, LMWH
Mappa
Vol 45 - N° 2
Articolo 101649- Marzo 2021 Ritorno al numero
Articolo precedente
- Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511
- Quanwu Su, Hongxia Wang
- A survey of lifestyle habits, physician counseling, and direct-to consumer genetic testing in patients with hereditary hemochromatosis
- Andree H. Koop, Hassan M. Ghoz, Fernando F. Stancampiano, Katie Nordelo, William C. Palmer
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?